Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of winged needle and syringe pump administration of PHESGO in HER2-positive breast cancer
jRCT1041230177Active, not recruiting
- Sponsor
- Shibata Takashi
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of trastuzumab in breast cancer, sponsored by Shibata Takashi. Primary endpoint: Injection site reaction presence or absence. Started Mar 2024; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT1041230177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041230177.